Top

Published in:

01-06-2011 | Preclinical study

Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G₂/M checkpoint signaling

Authors: Christoforos G. Thomas, Anders Strom, Karolina Lindberg, Jan-Ake Gustafsson

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

Estrogen receptor beta (ERβ) inhibits proliferation in different cellular systems by regulating components of the cell cycle machinery. Eukaryotic cells respond to DNA damage by arresting in G₁, S, or G₂ phases of the cell cycle to initiate DNA repair. Most tumor cells due to disruptions in the p53-dependent G₁ pathway are dependent on S-phase and G₂/M checkpoints to maintain genomic integrity in response to DNA damage. We report that induction of ERβ expression causes abrogation of the S-phase, and the Chk1/Cdc25C-mediated G₂/M checkpoints after cisplatin and doxorubicin exposure in p53-defective breast cancer cells but not in p53 wild-type mammary cells. This impairment of DNA damage response that involves BRCA1 downregulation and caspase-2 activation results in mitotic catastrophe and decreased cancer cell survival. These results indicate that in cancers where p53 is defective, assessment of the presence of ERβ may be of predictive value for the successful response to chemotherapy.

Available only for authorised users

Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629–634PubMedCrossRef

Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604PubMedCrossRef

Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310PubMedCrossRef

Dixon H, Norbury CJ (2002) Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 1:362–368PubMedCrossRef

Scully R, Chen J, Plug A et al (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88:265–275PubMedCrossRef

Yamane K, Schupp JE, Kinsella TJ (2007) BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage. Cancer Res 67:6286–6292PubMedCrossRef

Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls homology-directed DNA repair. Mol Cell 4:511–518PubMedCrossRef

Xu X, Weaver Z, Linke SP et al (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389–395PubMedCrossRef

10.

Shen SX, Weaver Z, Xu X et al (1998) A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17:3115–3124PubMedCrossRef

11.

Tassone P, Di Martino MT, Ventura M et al (2009) Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 8:648–653PubMed

12.

Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRef

13.

Powell SN, Kachnic LA (2008) Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 8:448–460PubMed

14.

Wu K, Jiang SW, Couch FJ (2003) p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. J Biol Chem 278:15652–15660PubMedCrossRef

15.

Arizti P, Fang L, Park I et al (2000) Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20:7450–7459PubMedCrossRef

16.

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93:5925–5930PubMedCrossRef

17.

Gustafsson JA (1999) Estrogen receptor beta—a new dimension in estrogen mechanism of action. J Endocrinol 163:379–383PubMedCrossRef

18.

Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120–4130PubMedCrossRef

19.

Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101:1566–1571PubMedCrossRef

20.

Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66:11207–11213PubMedCrossRef

21.

Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423–428PubMedCrossRef

22.

Jin W, Chen Y, Di GH et al (2008) Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter. J Biol Chem 283:29671–29680PubMedCrossRef

23.

Kravchenko JE, Ilyinskaya GV, Komarov PG et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A 105:6302–6307PubMedCrossRef

24.

Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421–429PubMedCrossRef

25.

Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825–2837PubMedCrossRef

26.

Castedo M, Perfettini JL, Roumier T et al (2004) The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23:4353–4361PubMedCrossRef

27.

Zhivotovsky B, Orrenius S (2005) Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331:859–867PubMedCrossRef

28.

Sidi S, Sanda T, Kennedy RD et al (2008) Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133:864–877PubMedCrossRef

29.

Menendez D, Inga A, Resnick MA (2010) Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci U S A 107:1500–1505PubMedCrossRef

30.

Bolderson E, Richard DJ, Zhou BB, Khanna KK (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15:6314–6320PubMedCrossRef

31.

Dunphy WG, Kumagai A (1991) The cdc25 protein contains an intrinsic phosphatase activity. Cell 67:189–196PubMedCrossRef

32.

Pines J, Hunter T (1991) Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 115:1–17PubMedCrossRef

33.

Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501–1505PubMedCrossRef

34.

Kumagai A, Dunphy WG (1996) Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273:1377–1380PubMedCrossRef

35.

Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A (2009) Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 69:5793–5800PubMedCrossRef

36.

Tordai A, Wang J, Andre F et al (2008) Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10:R37PubMedCrossRef

37.

Duong V, Boulle N, Daujat S et al (2007) Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 67:5513–5521PubMedCrossRef

38.

Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, Resnick MA (2007) A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol 27:2590–2600PubMedCrossRef

39.

Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11:175–189PubMedCrossRef

Title: Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling
Authors: Christoforos G. Thomas
Anders Strom
Karolina Lindberg
Jan-Ake Gustafsson
Publication date: 01-06-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1011-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer

Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients

PALB2 analysis in BRCA2-like families

Erratum to: Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

Three-dimensional collagen represses cyclin E1 via β1 integrin in invasive breast cancer cells

Further studies based on better design are needed to explore the association of NPAS2 gene polymorphisms with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer